Payment overview · 2025
General Payments
$129.97
7 reported records · 6 companies
Healthcare provider profile · identity verified
Tannis Alligood, MD
Allopathic & Osteopathic Physicians|Family Medicine · NAHUNTA, GA · NPI 1265457717
Verified facts
What the public records show
CMS Open Payments records show Tannis Alligood, MD received $129.97 in general payments during 2025 across 7 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.83 | 34.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.50 | 16.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.63 | 13.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.37 | 12.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.47 | 11.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.17 | 10.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $129.97 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.83 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 66 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
89 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 597 | 166 |
| Atorvastatin Calcium | Atorvastatin Calcium | 586 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 502 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 491 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 484 | 76 |
| Omeprazole | Omeprazole | 446 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 440 | 72 |
| Montelukast Sodium | Montelukast Sodium | 400 | 58 |
| Gabapentin | Gabapentin | 397 | 76 |
| Lisinopril | Lisinopril | 396 | 76 |
| Ropinirole Hcl | Ropinirole Hcl | 370 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 359 | 93 |
| Simvastatin | Simvastatin | 345 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 304 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 285 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 283 | 79 |
| Meloxicam | Meloxicam | 278 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 276 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 276 | 50 |
| Losartan Potassium | Losartan Potassium | 268 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 256 | 28 |
| Furosemide | Furosemide | 250 | 54 |
| Metformin Hcl | Metformin Hcl | 244 | 53 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 242 | 60 |
| Trazodone Hcl | Trazodone Hcl | 222 | 27 |
| Potassium Chloride | Potassium Chloride | 207 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 59 |
| Carvedilol | Carvedilol | 199 | 28 |
| Sertraline Hcl | Sertraline Hcl | 199 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 190 | 51 |
| Alendronate Sodium | Alendronate Sodium | 187 | 31 |
| Tramadol Hcl | Tramadol Hcl | 186 | 43 |
| Glipizide Er | Glipizide | 185 | 38 |
| Eliquis | Apixaban | 164 | 20 |
| Buspirone Hcl | Buspirone Hcl | 156 | 22 |
| Famotidine | Famotidine | 154 | 39 |
| Donepezil Hcl | Donepezil Hcl | 151 | suppressed |
| Pregabalin | Pregabalin | 146 | 19 |
| Alprazolam | Alprazolam | 142 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 139 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 132 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 123 | 20 |
| Ezetimibe | Ezetimibe | 119 | 20 |
| Ozempic | Semaglutide | 119 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 114 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 113 | 14 |
| Prednisone | Prednisone | 110 | 82 |
| Allopurinol | Allopurinol | 109 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 105 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 101 | 29 |
| Myrbetriq | Mirabegron | 101 | suppressed |
| Januvia | Sitagliptin Phosphate | 100 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 100 | 14 |
| Estradiol | Estradiol | 97 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 97 | 16 |
| Sucralfate | Sucralfate | 94 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 16 |
| Mirtazapine | Mirtazapine | 93 | suppressed |
| Fenofibrate | Fenofibrate | 90 | 18 |
| Farxiga | Dapagliflozin Propanediol | 89 | 14 |
| Clonidine Hcl | Clonidine Hcl | 88 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 86 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 85 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 21 |
| Metformin Hcl Er | Metformin Hcl | 83 | 22 |
| Clonazepam | Clonazepam | 76 | 12 |
| Atenolol | Atenolol | 75 | 19 |
| Memantine Hcl | Memantine Hcl | 74 | suppressed |
| Lorazepam | Lorazepam | 73 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 14 |
| Bupropion Xl | Bupropion Hcl | 70 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 11 |
| Jardiance | Empagliflozin | 66 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 64 | 17 |
| Spironolactone | Spironolactone | 61 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 41 |
| Eszopiclone | Eszopiclone | 58 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 29 |
| Diazepam | Diazepam | 54 | suppressed |
| Baclofen | Baclofen | 53 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 53 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 53 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 53 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 12 |
| Celecoxib | Celecoxib | 51 | 11 |
| Chlorthalidone | Chlorthalidone | 51 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | suppressed |
| Glimepiride | Glimepiride | 48 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 47 | 12 |
| Meclizine Hcl | Meclizine Hcl | 47 | 15 |
| Nystatin | Nystatin | 46 | 22 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Trulicity | Dulaglutide | 45 | suppressed |
| Linzess | Linaclotide | 43 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | suppressed |
| Methocarbamol | Methocarbamol | 41 | 13 |
| Azithromycin | Azithromycin | 40 | 36 |
| Fluconazole | Fluconazole | 40 | 22 |
| Ibuprofen | Ibuprofen | 40 | 14 |
| Nabumetone | Nabumetone | 39 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 27 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 13 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 23 | suppressed |
| Nystop | Nystatin | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Digoxin | Digoxin | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Progesterone | Progesterone, Micronized | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Ubrelvy | Ubrogepant | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Indomethacin | Indomethacin | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Cimetidine | Cimetidine | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Cymbalta | Duloxetine Hcl | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129.97 · 7 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, JARDIANCE, Ozempic, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error